Table 1.
Demographic and clinical characteristics of patients
| training cohort | validation cohort | |||
|---|---|---|---|---|
| Characters | n=616 | n=152 | P-value | |
| Gender, male/femeal | 514/102 | 131/21 | 0.409 | |
| Age, <60/≥60 | 343/273 | 80/72 | 0.498 | |
| HBsAg, | ||||
| negative/positive | 100/516 | 27/125 | 0.649 | |
| AFP | ||||
| <400/≥400 ng/mL | 435/181 | 113/39 | 0.363 | |
| TBIL | ||||
| <20/≥20 µmol/L | 558/58 | 136/16 | 0.678 | |
| GGT, <45/≥45 U/L | 248/368 | 63/89 | 0.789 | |
| ALT, <50/≥50 U/L | 495/121 | 119/33 | 0.569 | |
| ALB, <35/≥35g/L | 21/595 | 45/107 | <0.001 | |
| CRP, <10/≥10mg/L | 549/67 | 136/16 | 0.901 | |
| FIB,<266/≥266mg/L | 399/217 | 102/50 | 0.589 | |
| PLT | ||||
| <200/≥200 10^9/L | 509/107 | 124/28 | 0.76 | |
| cirrhosis,no/yes | 156/460 | 37/115 | 0.802 | |
| tumor number, | ||||
| single/multiple | 533/83 | 127/25 | 0.345 | |
| tumor throbus | ||||
| no/yes | 577/39 | 143/9 | 0.852 | |
| tumor capsule | ||||
| no/yes | 394/222 | 103/49 | 0.38 | |
| tumor size | ||||
| <5/≥5cm | 360/256 | 78/74 | 0.112 | |
| LNM | ||||
| no/yes | 612/4 | 150/2 | 0.403 | |
| MVI, no/yes | 450/166 | 102/50 | 0.144 | |
| differentiation, | ||||
| I-II/III-IV | 421/195 | 102/48 | 0.985 | |
| IBS, 0/1 | 12/551/52 | 39/103/10 | <0.001 | |
| GPS, 0/1/2 | 535/73/8 | 132/20/0 | 0.342 | |
| IBI,0/1/2 | 322/294 | 80/70 | 0.711 | |
| FC-score,0/1/2 | 386/176/54 | 97/44/11 | 0.832 | |
| BCLC, A/B/C | 401/186/29 | 91/52/9 | 0.468 | |
| CLIP, 0/1-3/4-6 | 337/272/7 | 87/61/4 | 0.287 | |
APF, alpha fetal protein; FIB, fibrinogen; PLT, platelet; LNM, lymph node metastasis; MVI, microvascular invasion; IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.